---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003936"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:17:48.406565+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viridian promotes Tom Ciulla to CMO; details 2024 TED trial timelines and FcRn milestones

## Summary
- Dr. Thomas Ciulla promoted to CMO, succeeding Dr. Barrett Katz who becomes consultant; Dr. Katz receives severance and consulting fee.
- Topline results from THRIVE Phase 3 (active TED) expected mid-2024; THRIVE-2 (chronic TED) by year-end 2024.
- Subcutaneous VRDN-003 pivotal study expected to start mid-2024 pending regulatory alignment.
- FcRn portfolio: VRDN-006 IND by year-end 2024; VRDN-008 NHP data in 2H 2024.
- Inducement grant of 62,000 stock options to new employee outside equity plan.

## SEC filing metadata
- accession: 0001193125-24-003936
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524003936/0001193125-24-003936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524003936/d109329d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003936
- JSON: https://secwatch.observer/filing/0001193125-24-003936.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003936.txt

## Key facts
- Executive change
  Dr. Thomas Ciulla was appointed as Chief Medical Officer at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: Chief Medical Officer
  source text: The Board of Directors of the Company appointed Dr. Thomas Ciulla, formerly the Company’s Chief Development Officer since February 2023, as Chief Medical Officer of the Company effective January 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312524003936/0001193125-24-003936-index.htm
- Executive change
  Dr. Barrett Katz departed as Chief Medical Officer at Viridian Therapeutics, Inc.\DE.
  - Action: ceased to serve
  - Role: Chief Medical Officer
  source text: On January 3, 2024, after discussions with Viridian Therapeutics, Inc. (the “Company”) regarding his future plans, Dr. Barrett Katz, age 74, transitioned to a consulting role and ceased to serve as Chief Medical Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312524003936/0001193125-24-003936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.